Can The "More" Treatment Approach Cure Myeloma?
Posted: Nov 10, 2014
Can The "More" Treatment Approach Cure Myeloma? image

Here's one radio program you won't want to miss! Cure Panel interviews Dr. Gareth Morgan from top myeloma treatment facility University of Arkansas Medical Center (UAMS) on Tuesday, November 18 at 5PM Eastern Standard Time. The "Total Therapy" protocol for myeloma patients was developed at UAMS and the facility boasts some of the best myeloma survival rates in the world. On this show, Dr. Morgan will approach the "More Can Cure" approach, which has, and will continue to, be a very hot topic in the myeloma community. According to patient advocate and myeloma survivor himself, Gary Petersen, he writes on his blog. Myeloma Survival (www.myelomasurvival.com), many questions come to mind for this program, like:

  • How will UAMS' program change under the new leadership of Dr. Morgan?
  • UAMS has conducted clinical trials, however, they were usually UAMS-specific trials only. Will UAMS continue this strategy or will they be involved in the new monoclonal antibody clinical trials?

Mark your calendar and be sure to participate in this radio program. To pre-submit questions, email them to Priya@trialx.com. To listen in on the program, simply dial 718.664.6574 from the USA during show time or visit the Cure Talk Channel on BlogTalk Radio.

Here's one radio program you won't want to miss! Cure Panel interviews Dr. Gareth Morgan from top myeloma treatment facility University of Arkansas Medical Center (UAMS) on Tuesday, November 18 at 5PM Eastern Standard Time. The "Total Therapy" protocol for myeloma patients was developed at UAMS and the facility boasts some of the best myeloma survival rates in the world. On this show, Dr. Morgan will approach the "More Can Cure" approach, which has, and will continue to, be a very hot topic in the myeloma community. According to patient advocate and myeloma survivor himself, Gary Petersen, he writes on his blog. Myeloma Survival (www.myelomasurvival.com), many questions come to mind for this program, like:

  • How will UAMS' program change under the new leadership of Dr. Morgan?
  • UAMS has conducted clinical trials, however, they were usually UAMS-specific trials only. Will UAMS continue this strategy or will they be involved in the new monoclonal antibody clinical trials?

Mark your calendar and be sure to participate in this radio program. To pre-submit questions, email them to Priya@trialx.com. To listen in on the program, simply dial 718.664.6574 from the USA during show time or visit the Cure Talk Channel on BlogTalk Radio.

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation.